Effect of atorvastatin on the lipid profile, markers of immune inflammation and symptomatic severity of heart failure in patients with myocarditis-Reference-Cited by-同舟云学术

Effect of atorvastatin on the lipid profile, markers of immune inflammation and symptomatic severity of heart failure in patients with myocarditis

Published:2020-12-15 Issue:3 Volume:22 Page:76-81
ISSN:2687-1424
Container-title:Bulletin of the Russian Military Medical Academy
language:
Short-container-title:Bulletin of the Russian Military Medical Academy

Author:

Ryzhman N. N.,Grishaev S. L.,Cherkashin D. V.,Gladysheva E. V.,Filippov V. Yu.,Kutelev G. G.

Abstract

Abstract. The effect of atorvastatin on the immune system and lipid metabolism after 24-week treatment of patients with chronic myocarditis is considered. Statins have been found to improve the clinical course of heart failure with a preserved ejection fraction in patients with myocarditis: they reduce the functional class of heart failure, improve the systolic function of the heart and its arrhythmogenic potential. Despite the large amount of conflicting data in the field of statin use in heart failure, one can think about the possible influence of molecular differences in statins on their pharmacological and pleiotropic effects. In particular, atorvastatin, which has lipophilic properties, is able to penetrate cardiomyocytes in contrast to hydrophilic rosuvastatin, which may partially explain the positive cardiac effects of atorvastatin in patients with heart failure with a preserved ejection fraction. The probable basis for the positive effect of atorvastatin on morphofunctional parameters in heart failure is its positive pleiotropic effects associated with a decrease in рro-inflammatory immune markers and subsequent leveling of negative neurohumoral activation. An additional mechanism that caused the positive effect of atorvastatin on the clinical course of heart failure can be considered a factor of preservation of systolic function of the left ventricle.

Publisher

ECO-Vector LLC

Reference23 articles.

1. Аронов, Д.М. Плейотропные эффекты статинов / Д.М. Аронов // Кардиология. – 2008. – № 8 (48). – С. 60–68.

2. Гришаев, С.Л. Влияние терапии аторвастатином на клиническое течение хронической сердечной недостаточности неишемического генеза / С.Л. Гришаев [и др.] // Вестн. СПбГУ. – Сер. 11. Медицина. – 2016. – Вып. 4. – C. 15–25.

3. Лишманов, Ю.Б. Радионуклидная диагностика для практических врачей: практическое руководство / Ю.Б. Лишманов, В.И. Чернов. – Томск: STT, 2004. – 394 с.

4. Олейников, В.Э. Влияние аторвастатина на важнейшие механизмы аритмогенеза у больных инфарктом миокарда с подъемом сегмента ST / В.Э. Олейников [и др.] // Росс. кардиол. журн. – 2019. – № 7 (24). – С. 83–90.

5. Петрова, Т.Г. Влияние длительного приема статинов на течение воспалительных заболеваний пародонта у больных ишемической болезнью сердца / Т.Г. Петрова и [и др.] // Пародонтология. – 2019. – № 1 (24). – С. 88–90.